Velanne Asset Management Ltd lifted its stake in shares of Allergan plc (NYSE:AGN) by 4.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,632 shares of the company’s stock after buying an additional 1,710 shares during the period. Allergan comprises about 4.4% of Velanne Asset Management Ltd’s holdings, making the stock its 14th largest position. Velanne Asset Management Ltd’s holdings in Allergan were worth $6,388,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently made changes to their positions in the company. JNBA Financial Advisors purchased a new position in shares of Allergan during the fourth quarter valued at approximately $30,000. Washington Trust Bank lifted its holdings in Allergan by 166.7% during the first quarter. Washington Trust Bank now owns 240 shares of the company’s stock worth $35,000 after acquiring an additional 150 shares during the period. IMS Capital Management bought a new stake in Allergan during the third quarter worth $66,000. Bruderman Asset Management LLC bought a new stake in Allergan during the fourth quarter worth $49,000. Finally, Ruggie Capital Group bought a new stake in Allergan during the fourth quarter worth $53,000. 80.65% of the stock is currently owned by institutional investors.
In related news, Chairman Brent L. Saunders bought 1,760 shares of the stock in a transaction dated Thursday, March 7th. The stock was bought at an average price of $143.67 per share, with a total value of $252,859.20. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.08% of the company’s stock.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, January 29th. The company reported $4.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.15 by $0.14. Allergan had a positive return on equity of 8.18% and a negative net margin of 32.28%. The firm had revenue of $4.08 billion during the quarter, compared to analysts’ expectations of $4 billion. During the same period in the prior year, the business earned $4.86 EPS. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. Equities analysts predict that Allergan plc will post 16.37 EPS for the current fiscal year.
Allergan announced that its board has authorized a share repurchase plan on Tuesday, January 29th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
A number of analysts recently commented on AGN shares. Leerink Swann set a $217.00 price target on Allergan and gave the stock a “buy” rating in a report on Thursday, March 7th. Credit Suisse Group lowered Allergan from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $197.00 to $161.00 in a report on Thursday, January 31st. ValuEngine lowered Allergan from a “sell” rating to a “strong sell” rating in a report on Thursday, April 4th. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Finally, TheStreet lowered Allergan from a “c” rating to a “d+” rating in a report on Tuesday, January 29th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $188.14.
ILLEGAL ACTIVITY NOTICE: “Velanne Asset Management Ltd Has $6.39 Million Position in Allergan plc (AGN)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4299330/velanne-asset-management-ltd-has-6-39-million-position-in-allergan-plc-agn.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.